LyGenesis, Inc.
LyGenesis is a clinical-stage biotechnology company that transforms a patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs. Their innovative cell therapies aim to address large unmet medical needs such as end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorders. They utilize outpatient endoscopic ultrasound procedures to engraft cells, which reduces medical risks and costs compared to traditional organ transplantation. Their pipeline includes therapies for liver, thymus, pancreas, and kidney regeneration, with ongoing clinical trials and collaborations to develop novel treatments.
Industries
Nr. of Employees
small (1-50)
LyGenesis, Inc.
Headquartered in Pittsburgh, Pennsylvania
Products
Allogeneic hepatocyte cell therapy for end-stage liver disease (clinical candidate)
Donor-derived hepatocyte cell therapy intended for engraftment into patient lymph nodes to generate ectopic liver tissue; currently evaluated in a Phase 2a clinical trial for patients with end-stage liver disease.
Preclinical ectopic organ programs (pancreas, thymus, kidney; orphan pediatric indications)
Pipeline programs to generate ectopic pancreas (for Type 1 diabetes), thymus (aging/other indications), kidney (end-stage renal disease), and combination drug–biologic approaches for inborn errors of metabolism using biomaterial delivery and targeted engraftment strategies.
Allogeneic hepatocyte cell therapy for end-stage liver disease (clinical candidate)
Donor-derived hepatocyte cell therapy intended for engraftment into patient lymph nodes to generate ectopic liver tissue; currently evaluated in a Phase 2a clinical trial for patients with end-stage liver disease.
Preclinical ectopic organ programs (pancreas, thymus, kidney; orphan pediatric indications)
Pipeline programs to generate ectopic pancreas (for Type 1 diabetes), thymus (aging/other indications), kidney (end-stage renal disease), and combination drug–biologic approaches for inborn errors of metabolism using biomaterial delivery and targeted engraftment strategies.
Services
Joint development of preclinical proof-of-concept programs combining external cell sources or immunomodulatory platforms with lymph-node-based engraftment to advance specific indications (e.g., type 1 diabetes, immune tolerance evaluation).
Design, planning, and operational execution support for early-stage clinical studies of cell therapies, including Phase 2a sponsorship and site trial management.
Joint preclinical assessment of localized immune-modulatory biomaterials/proteins alongside implanted cells to evaluate potential to obviate chronic systemic immunosuppression.
Joint development of preclinical proof-of-concept programs combining external cell sources or immunomodulatory platforms with lymph-node-based engraftment to advance specific indications (e.g., type 1 diabetes, immune tolerance evaluation).
Design, planning, and operational execution support for early-stage clinical studies of cell therapies, including Phase 2a sponsorship and site trial management.
Joint preclinical assessment of localized immune-modulatory biomaterials/proteins alongside implanted cells to evaluate potential to obviate chronic systemic immunosuppression.
Expertise Areas
- Ectopic organ regeneration
- Cell therapy development (allogeneic)
- Cellular manufacturing and cGMP processing
- Preclinical animal modeling and translational validation
Key Technologies
- Allogeneic hepatocyte isolation
- In vivo ectopic organogenesis in lymph nodes
- Endoscopic ultrasound-guided cell delivery
- cGMP-compliant cell processing
News & Updates
LyGenesis has initiated a Phase 2a clinical trial evaluating its allogenic regenerative cell therapy for end-stage liver disease, marking a significant milestone in its development pipeline.
Biotechnology firm LyGenesis has injected donor cells into a person with liver failure for the first time, aiming to grow new organs inside patients.
LyGenesis has initiated a Phase 2a clinical trial evaluating its allogenic regenerative cell therapy for end-stage liver disease, marking a significant milestone in its development pipeline.
Biotechnology firm LyGenesis has injected donor cells into a person with liver failure for the first time, aiming to grow new organs inside patients.